PT-141 (bremelanotide) side effects: trial-grade data led by nausea, plus a blood-pressure flag

Almost every peptide we cover has a side-effect list pieced together from small studies and forum reports. PT-141 — pharmacologically bremelanotide — is the exception, because it cleared the FDA as Vyleesi and therefore carries a genuine, trial-grade adverse-event record from its phase-3 program and prescribing label.^[1] That is a real advantage: instead of guessing, we can read frequencies straight off controlled data. For the efficacy picture, see the PT-141 evidence monograph; this page is about what the molecule does that you don’t want.

The standout: nausea

The single most prominent adverse effect is nausea. Across the clinical development program it was the most frequently reported event — on the order of 40% of treated women — and it was the leading reason participants discontinued.^[2] It clustered around the first dose and tended to ease with subsequent use, but for a meaningful minority it was enough to abandon treatment.^[2] In the pivotal trials, a small share of women also took an anti-nausea medication alongside it.^[3] This is not a fringe effect to footnote; it is the defining tolerability problem of the drug.

Flushing, headache and injection-site reactions

Below nausea sit the everyday effects. Flushing — a warm reddening of the skin — and headache were the next most common, both consistent with a melanocortin agonist acting on vascular tone and central pathways.^[2] Because the approved product is a subcutaneous injection, injection-site reactions (redness, itching, a small lump) also show up, though less often.^[4] None of these is dangerous on its own; they are the kind of predictable, mechanism-linked nuisances that come with an on-demand injectable.

The flagged one: a transient blood-pressure rise

Focal skin darkening from repeated dosing

A melanocortin agonist acts on the same receptor family that drives pigmentation, so it is no surprise that focal hyperpigmentation — darker patches of skin — is a documented effect, and it becomes more likely with repeated dosing.^[4] The darkening has been reported on the face, gums and breasts, and it does not always fade fully once it appears.^[4] Women with darker complexions or a history of pigmentation changes were noted to be more susceptible, which is why the label frames it as a reason to limit how often the drug is used.^[4] It is a cosmetic effect rather than a dangerous one, but a potentially permanent cosmetic effect is not trivial.

How off-label and male community dosing amplifies all of this

Everything above was measured in premenopausal women dosed at the approved 1.75 mg, on demand, with hard caps of one dose a day and eight a month.^[1] Most online PT-141 use looks nothing like that. It is sold as research-chemical powder, used by men and for general libido purposes the approval never covered, and frequently reconstituted and dosed by the milligram in amounts that run higher than 1.75 mg with no ceiling and no clinician.^[3] Because nausea, the blood-pressure swing and the pigmentation effect all scale with dose and dosing frequency, taking more — or taking it more often — turns up the volume on each of them, while removing the monitoring the label was built around. The trial data is reassuring only within the schedule it was generated under. For why the math behind a reconstituted dose is so easy to get wrong, see our reconstitution calculator.

The honest bottom line

PT-141’s side-effect profile is unusually trustworthy because it rests on a real approval rather than anecdote. The dominant problem is nausea; the milder companions are flushing, headache and injection-site reactions; and the two effects that actually drive the cautions are a transient post-dose blood-pressure rise and focal skin darkening with repeated use.^[2][4] Within the approved population and schedule, that profile is manageable for someone screened for cardiovascular risk. Outside it — higher off-label doses, male use, gray-market vials of uncertain strength — you keep all the same effects but lose the dose discipline and supervision that made them acceptable. See also the PT-141 dosage guide for exactly where the approved schedule ends and the guesswork begins.